Clinical Trials for Ovarian Cancer

Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally recurrent ovarian, fallopian tube, primary peritoneal, endometrial, cervical, or vaginal cancers confined to the abdomen/pelvis receive daily oral talazoparib, a PARP1/2 inhibitor and potent PARP trapper/radiosensitizer, starting before and during fractionated external-beam radiation. Eligible patients must have ECOG 0–1 (or adequate life expectancy), adequate organ function, and at least one non-previously-irradiated measurable lesion; prior RT to the planned field, carcinomatosis/ascites/hepatic metastases, or need for extended-field RT are excluded.

ClinicalTrials.gov ID: NCT03968406

Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Metastatic, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer (initially platinum-sensitive; ≤1 prior line for platinum-resistant disease; prior PARP allowed) treated with PLX038, a long-acting pegylated prodrug of SN-38 (topoisomerase I inhibitor) given IV every 21 days until progression/toxicity. Excludes non–HGS histology and patients with UGT1A1 deficiency (e.g., Gilbert’s or homozygous UGT1A1*28).

ClinicalTrials.gov ID: NCT05465941

A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, platinum-resistant epithelial ovarian cancer whose tumors are TAG72-positive receive lymphodepleting fludarabine/cyclophosphamide followed by a single intraperitoneal infusion of autologous TAG72-directed CAR T cells. Investigational therapy targets the TAG72 glycoprotein to mediate CAR T–cell killing of peritoneal ovarian cancer; single-arm dose-escalation with long-term follow-up.

ClinicalTrials.gov ID: NCT05225363

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with platinum-refractory or -resistant ovarian, fallopian tube, or primary peritoneal carcinoma (any prior lines; prior anti-VEGF allowed; ECOG 0–1) to receive weekly paclitaxel plus bevacizumab with added lurbinectedin. Lurbinectedin is a DNA minor-groove binding transcription inhibitor (RNA Pol II degradation) with myelosuppression risk; study defines a safe dose and assesses preliminary activity.

ClinicalTrials.gov ID: NCT05636111

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for adults with recurrent primary mucinous ovarian cancer (ECOG 0–2) undergoing secondary cytoreductive surgery followed by intraoperative HIPEC using cisplatin. Aims to improve progression-free survival with a locoregional approach (heat-enhanced, DNA crosslinking cytotoxic agent) while evaluating perioperative toxicity and quality of life.

ClinicalTrials.gov ID: NCT05123807

A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB-101, an Autologous Mesothelin (MSLN) CAR T Cell Therapy With Antigen-dependent Expression of OUTSMART™ Designed IL-2 Cytokine in Platinum-resistant Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, recurrent platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer after at least two chemotherapy lines receive a one-time infusion of OPB-101. This autologous CAR T-cell therapy targets mesothelin and expresses a designed IL-2 cytokine upon antigen recognition.

ClinicalTrials.gov ID: NCT07030907

A Phase I Clinical Trial of an Infusion of Autologous T Cells Genetically Engineered With a Chimeric Receptor to Target the Follicle-Stimulating Hormone Receptor in Patients With Recurrent Ovarian Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal, or select sex cord-stromal tumors (platinum-resistant/refractory after ≥1 platinum and ≥2 prior systemic regimens; measurable/detectable disease; ECOG 0–2) receive a single infusion of autologous T cells engineered with a chimeric endocrine receptor targeting FSHR, delivered intraperitoneally or intravenously across escalating dose levels. Investigational product: FSHR-targeted CAR-like T cells designed for antigen-directed activation/cytotoxicity against FSHR-expressing tumors.

ClinicalTrials.gov ID: NCT05316129

The Efficacy of T-regulatory Cell Depletion with E7777 Combined with Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent/metastatic solid tumors that progressed on standard therapy (Phase I: pembrolizumab-appropriate tumors; expansion: platinum-resistant ovarian cancer without prior PD-1/PD-L1 and MSI-H cancers post–PD-1/PD-L1) receive pembrolizumab plus E7777 (denileukin diftitox), a CD25-directed IL-2–diphtheria toxin fusion that depletes T-regulatory cells. E7777 is given days 1–3 of 21-day cycles (dose-escalation to RP2D, up to 8 cycles) with fixed-dose pembrolizumab, continuing until progression/toxicity.

ClinicalTrials.gov ID: NCT05200559

An Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of the CTPS1 Inhibitor STP938 in Adult Subjects With Advanced Solid Tumors, With a Safety Expansion in Advanced CTPS2 Null Ovarian Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, incurable solid tumors receive oral STP938 (dencatistat) monotherapy; a safety expansion focuses on patients with CTPS2-null ovarian cancer. STP938 inhibits CTPS1, an enzyme involved in nucleotide synthesis.

ClinicalTrials.gov ID: NCT06297525

Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients With Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-arm study for adults with platinum-resistant or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer (measurable disease, ECOG 0–1; prior lines allowed) testing weekly paclitaxel plus oral ONC201 (dordaviprone), an investigational DRD2/3 antagonist that activates the integrated stress response and inhibits Akt/ERK signaling, with ONC201 continuation permitted if paclitaxel stops. Evaluates safety and preliminary efficacy (ORR/PFS), with PK/PD and immune correlatives.

ClinicalTrials.gov ID: NCT04055649